Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Bibliographic Details
Main Authors: Patel, Sapna, Milhem, Mohammed, Hallmeyer, Sigrun, Daniels, Gregory, Cranmer, Lee, Taback, Bret, Flaherty, Lawrence, Aung, Sandra, Lowder, James, Sharfman, William
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/

Similar Items